GlassScriptPhysician profile
Kent A Hufford
NPI 1487659272
$11,850.97
in general payments reported to CMS, 2019-2025
45 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,253 · 2020: $1,543 · 2021: $2,038 · 2022: $1,130 · 2023: $1,502 · 2024: $1,742 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,887.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,224.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,134.65 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $858.15 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $799.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $792.73 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $506.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.57 | 2020-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $420.18 | 2019-2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $405.04 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $404.59 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $378.88 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $308.75 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Abbvie INC. | $277.99 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $257.85 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $239.02 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Hufford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.